文献速递乳腺MR乳腺X线

简化乳腺磁共振成像(MRI)或数字乳腺断层合成在致密乳腺中检测乳腺癌?一项结果可比的回顾性初步研究

Abbreviated breast magnetic resonance imaging (MRI) or digital breast tomosynthesis for breast cancer detection in dense breasts? A retrospective preliminary study with comparable results.
PubMed 文献 · Clin Radiol · 2024-01-10

该单中心横断面研究纳入115例乳腺密度为C或D且行简化乳腺MRI(AB-MR)的女性,以组织病理为参考标准比较AB-MR与数字乳腺断层合成(DBT)对164个病灶的检出效能;DBT与AB-MR敏感度均为98.5%,AB-MR特异度43.9%高于DBT的34.6%,两者对低风险病灶均有高阴性预测值。

要点

  • DBT与AB-MR对致密乳腺乳腺癌检出敏感度均为98.5%,AB-MR特异度43.9%高于DBT的34.6%。
  • AB-MR漏诊1个低级别导管原位癌(DCIS),占恶性病灶0.6%。
  • DBT未检出61个病灶,其中46个(75.4%)位于密度C乳腺。

核心结论

  • 研究结果提示,DBT与AB-MR作为致密乳腺女性乳腺癌检测方法效能相当,且对低风险病灶均有高阴性预测值。

研究设计与样本

  • 单中心横断面研究,纳入2018年6月至2021年12月间115例DBT乳腺密度为ACR BI-RADS C或D且伴乳腺病灶并接受AB-MR的女性。
  • AB-MR在3 T MRI系统上进行,成像方案包括三个序列:轴位T1脂肪饱和平扫、轴位首期增强扫描、以及首期增强减影最大强度投影(MIP)。
  • DBT与AB-MR图像由两名对组织病理和患者结局设盲的放射科医生评估,以组织病理为参考标准。

关键影像表现/征象

  • 164个组织病理证实病灶中69个(42.1%)为恶性、95个(57.9%)为良性。
  • DBT检出62.8%(103/164)病灶,检出全部恶性病灶100%(69/69)及35.7%(34/95)良性病灶。
  • AB-MR检出65.2%(107/164)病灶,检出98.6%(68/69)恶性病灶及41.1%(39/95)良性病灶。
  • 未检出61个病灶中46个(75.4%)位于密度C乳腺、15个(24.6%)位于密度D乳腺。

诊断标准与关键数值

  • DBT敏感度98.5%、特异度34.6%、阳性预测值66.3%、阴性预测值94.7%。
  • AB-MR敏感度98.5%、特异度43.9%、阳性预测值67.2%、阴性预测值96.2%。
  • AB-MR漏诊1个恶性病灶(0.6%),为低级别导管原位癌(DCIS)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文标题注明为回顾性初步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To compare the diagnostic performance of abbreviated breast magnetic resonance (AB-MR) imaging (MRI) and digital breast tomosynthesis (DBT) for breast cancer detection in Malaysian women with dense breasts, using histopathology as the reference standard.

MATERIALS AND METHODS: This was a single-centre cross-sectional study of 115 women with American College of Radiology (ACR) Breast Imaging-Reporting and Data System (BIRADS) breast density C and D on DBT with breast lesions who underwent AB-MR from June 2018 to December 2021. AB-MR was performed on a 3 T MRI system with an imaging protocol consisting of three sequences: axial T1 fat-saturated unenhanced; axial first contrast-enhanced; and subtracted first contrast-enhanced with maximum intensity projection (MIP). DBT and AB-MR images were evaluated by two radiologists blinded to the histopathology and patient outcomes. Diagnostic accuracy (sensitivity, specificity, positive predictive value [PPV] and negative predictive value [NPV]) was assessed.

RESULT: Of the 115 women, the mean age was 50.6 years. There were 48 (41.7%) Malay, 54 (47%) Chinese, and 12 (10.4%) Indian women. The majority (n=87, 75.7%) were from the diagnostic population. Sixty-one (53.1%) were premenopausal and 54 (46.9%) postmenopausal. Seventy-eight (72.4%) had an increased risk of developing breast cancer. Ninety-one (79.1%) women had density C and 24 (20.9%) had density D. There were 164 histopathology-proven lesions; 69 (42.1%) were malignant and 95 (57.9%) were benign. There were 62.8% (n=103/164) lesions detected at DBT. All the malignant lesions 100% (n=69) and 35.7% (n=34) of benign lesions were detected. Of the 61 lesions that were not detected, 46 (75.4%) were in density C, and 15 (24.6%) were in density D. The sensitivity, specificity, PPV, and NPV for DBT were 98.5%, 34.6%, 66.3%, and 94.7%, respectively. There were 65.2% (n=107/164) lesions detected on AB-MR, with 98.6% (n=68) malignant and 41.1% (39) benign lesions detected. The sensitivity, specificity, PPV, and NPV for AB-MR were 98.5%, 43.9%, 67.2%, and 96.2%, respectively. One malignant lesion (0.6%), which was a low-grade ductal carcinoma in-situ (DCIS), was missed on AB-MR.

CONCLUSION: The present findings suggest that both DBT and AB-MR have comparable effectiveness as an imaging method for detecting breast cancer and have high NPV for low-risk lesions in women with dense breasts.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Ramli Hamid MT, Ab Mumin N, Abdul Hamid S, et al. Abbreviated breast magnetic resonance imaging (MRI) or digital breast tomosynthesis for breast cancer detection in dense breasts? A retrospective preliminary study with comparable results. Clin Radiol. 2024. PMID: 38267349. doi:10.1016/j.crad.2023.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。